论文部分内容阅读
目的观察阿德福韦酯(ADV)联合扶正化瘀胶囊治疗HBV DNA阴性代偿期肝硬化患者的疗效。方法 56例HBV DNA阴性代偿期肝硬化患者随机分为两组,对照组27例,给予常规保肝及抗纤维化治疗;治疗组29例,在对照组基础上加服ADV治疗。观察两组患者治疗前及治疗后12、24、36、48周时症状、体征、肝功能、血清肝纤维化指标及HBV DNA低于检测下限的比率。结果治疗48周后,与治疗前相比,治疗组症状、体征、肝功能及血清肝纤维化的指标显著恢复(P<0.05);与对照组相比,治疗组患者肝纤维化的指标改善及HBV DNA低于检测下限的比率更为显著。治疗组并发症例数和病死率显著低于对照组。结论 ADV联合扶正化瘀胶囊治疗HBV DNA阴性代偿期肝硬化具有显著的疗效。
Objective To observe the effect of adefovir dipivoxil (ADV) combined with Fuzhenghuayu Capsule in the treatment of patients with HBV DNA-negative compensated cirrhosis. Methods Fifty-six patients with HBV DNA-negative decompensated cirrhosis were randomly divided into two groups, control group (n = 27), conventional hepatoprotective and anti-fibrotic treatment. The treatment group (n = 29) received ADV treatment on the basis of the control group. The symptoms, signs, liver function, serum hepatic fibrosis indexes and the ratio of HBV DNA below the detection limit were observed before treatment and 12, 24, 36 and 48 weeks after treatment. Results After treatment for 48 weeks, the indexes of symptoms, signs, liver function and serum liver fibrosis were significantly recovered in treatment group compared with those before treatment (P <0.05). Compared with the control group, the indicators of liver fibrosis in treatment group were improved And HBV DNA below the detection limit of the more significant ratio. The treatment group complications and mortality was significantly lower than the control group. Conclusion ADV combined with Fuzhenghuayu capsule in the treatment of HBV DNA-negative decompensated cirrhosis has a significant effect.